OPEN ACCESS

Original research

Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis

Daniel P O Kaiser,[1,2] Ani Cuberi,[3] Jennifer Linn,[1] Matthias Gawlitza[1,2]

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/jnis-2022-019249).

[1]Department of Neuroradiology, University Hospital Carl Gustav Carus, Dresden, Germany
[2]EKFZ for Digital Health, Dresden University of Technology, Dresden, Germany
[3]Department of Radiology, University Hospital Carl Gustav Carus, Dresden, Germany

Correspondence to
Dr Matthias Gawlitza, Department of Neuroradiology, University Hospital Carl Gustav Carus, Dresden 01307, Germany; matthias.gawlitza@ukdd.de

Received 8 June 2022
Accepted 20 July 2022
Published Online First 2 August 2022

To cite: Kaiser DPO, Cuberi A, Linn J, *et al*. *J NeuroIntervent Surg* 2023;**15**:892–897.

ABSTRACT

Background Data on the safety and efficacy of flow diverters (FD) for the treatment of unruptured internal carotid artery (ICA) aneurysms with compressive neuro-ophthalmological symptoms (NOS) are scarce and comprise mainly small case series.

Methods We performed a search of three databases and included series with ≥10 patients, with unruptured aneurysms of the ICA and NOS, treated with FD. Random-effects analysis of treatment results and safety was performed.

Results A total of 22 studies reporting on 594 patients were included. Pooled proportions of NOS recovery, improvement, transient and permanent worsening were: 47.4% (95% CI 35.0% to 60.1%); 74.5% (95% CI 67.9% to 80.2%); 7.1% (95% CI 3.3% to 14.7%); and 4.9% (95% CI 3.2% to 7.4%), respectively. Rates of complete recovery and improvement in patients with isolated visual symptoms were 30.6% (95% CI 12.5% to 57.7%) and 56.6% (95% CI 42.3% to 69.9%). Isolated oculomotor symptoms recovered completely in 47.8% (95% CI 29.9% to 66.3%) and improved in 78% (95% CI 69.2% to 84.9%). Morbidity occurred in 5% (95% CI 2.8% to 9%) and mortality in 3.9% (95% CI 2% to 7.5%) of patients. An increased likelihood of symptom improvement was observed when treatment was performed early (<1 month) after symptom onset (OR=11.22, 95% CI 3.9% to 32.5%).

Conclusion Flow diversion promotes recovery or improvement of compressive symptoms in a large proportion of patients but is associated with significant rates of morbidity and mortality. Transient and permanent NOS worsening is not uncommon. Early treatment is of utmost importance, as it increases the likelihood of symptom improvement more than 10-fold.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ There are limited data in the literature on flow diversion for unruptured internal carotid artery (ICA) aneurysms with compressive neuro-ophthalmological symptoms.

WHAT THIS STUDY ADDS

⇒ This meta-analysis provides a comprehensive overview of the efficacy and safety of flow diversion in this specific patient population.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Flow diversion is an effective and valuable treatment strategy for patients with compressive ICA aneurysms and neuro-ophthalmological symptoms. However, it is important to treat patients early after symptom onset and to be aware of the non-negligible morbidity and mortality rate.

INTRODUCTION

Aneurysms of the internal carotid artery causing mass effect and neuro-ophthalmological symptoms (NOS) by compression of the cranial nerves (CN) are a rare pathology. Visual impairment or diplopia induced by CN palsy are disabling symptoms and of high relevance for the patient's quality of life. Aneurysms inducing compression-related symptoms are often large and/or rapidly growing lesions.[1] Intrasaccular coil embolization, parent artery occlusion (PAO)—either with or without extracranial–intracranial bypass surgery—or aneurysm clipping have been studied for the management of these lesions.[2–5] Flow diverters (FD) promote aneurysm collapse and healing, thus reducing the mass effect, while preserving the vessel patency.[6] To date, the literature on the use of FD in internal carotid artery (ICA) aneurysms causing compressive NOS is still scarce. The present study aims to provide a systematic review of the literature and meta-analysis of this treatment method, aiming to provide physicians involved in aneurysm treatment with a realistic pooled estimate of treatment efficacy and safety. Moreover, we sought to investigate the relevance of time lapse from symptom onset to treatment on the rates of symptom improvement.

METHODS

Ethics statement

Approval of the ethics committee was not required for this study as only published primary studies were analyzed. This study was not registered.

Search strategy

The senior author independently reviewed the literature on PubMed, Scopus, and Web of Science, using a predefined search algorithm (detailed in the online supplemental material). We searched titles, abstracts, and keywords. Duplicates were

removed, titles were screened and abstracts were reviewed. Second, if potentially eligible for this analysis, the full text paper was retrieved and reviewed thoroughly. The first and the senior author extracted the data and entered them into a predefined data sheet; discrepancies were solved by consensus.

Inclusion criteria

We included series reporting on ≥10 patients with (1) an unruptured intracranial aneurysm of the ICA, with (2) a compressive effect on the oculomotor nerves and/or the optic pathway, considered responsible for ocular symptoms—that is, (3) cranial neuropathy affecting the CN III, IV, and VI (alone or in combination) and/or (4) visual impairment due to compressive optic neuropathy. Treatment was (5) with flow diversion alone or in conjunction with coil embolization.

Data extraction and outcome measures

The objectives of this meta-analysis were to summarize the clinical and anatomical efficacy (compressive symptom improvement or complete recovery and aneurysm occlusion) and the safety (treatment-related thromboembolic and hemorrhagic complications with permanent deficit or death) of flow diversion for treatment of compressive ICA aneurysms with neuro-ophthalmological symptoms. Secondary endpoints were the rates of transient and permanent symptom worsening and the impact of time from symptom onset to treatment on the symptom improvement rate.

We extracted, with as much detail as possible, patient-, aneurysm-, and treatment-specific data from the original articles. If necessary and possible, values were recalculated from individual patient data provided in the publications—for example, in tables or the appendix. Data from the series of Boulouis *et al*[7] were calculated from the original raw dataset.

We extracted data on isolated visual or oculomotor symptoms, or a combination of both. CN deficits at follow-up were graded as 'complete recovery', 'partial recovery', and 'permanent worsening'. The sum of patients with 'complete recovery' and 'partial recovery' was defined as 'improvement'. Articles were furthermore screened for signs of 'transient worsening' of CN deficits after flow diversion.

Morbidity was defined as any neurological deterioration of the patient's status (except worsening of NOS), related to presumed hemorrhagic or ischemic complications.

Aneurysm occlusion grades were extracted at last follow-up using the widely accepted classification: 'aneurysm remnant', 'neck remnant', and 'complete occlusion'.[8] 'Neck remnant' and 'aneurysm remnant' were grouped as 'incomplete occlusion'. When an alternative grading scale was used,[9] only grade D was considered 'complete occlusion'.

Statistical analysis

The analysis was performed using primarily R Studio (R Studio, Boston, USA, version 2022.02.2) with the metafor[10] and meta[11] packages. Random-effect analyses were performed after logit transformation. Results are presented as percentage and 95% CI. I^2 statistic and Q-test were used to assess study heterogeneity. Publication bias was assessed by visual inspection of funnel plots and with Egger's unweighted regression test. Pooled effects of early versus late treatment (ie, within 1 month vs beyond 1 month after symptom onset) were calculated using the RevMan 5 software package,[12]

Table 1 Study overview

Study	Year	Design	Pts/pts with NOS* (%)	Flow diversion devices used	Dedicated NOS F/U	Comments
Yu *et al*[22]	2012	PM	143/14 (10.2%)	PED	NR	
Szikora *et al*[28]	2013	PS	29/16 (55.2%)	PED, Silk	NR	Overlap with PUFS/Sahlein *et al*[46]
O'Kelly *et al*[26]	2013	PM	97/36 (37.1%)	PED	No	Data discrepancy in the manuscript, data from text were used
Moon *et al*[35]	2014	RS	20/19 (95%)	PED	NR	Data recalculated
Tanweer *et al*[37]	2014	RS	41/19 (46.3%)	PED	Yes	Data discrepancy in the manuscript, data from text were used
Zanaty *et al*[34]	2014	RS	157/51 (33.8%)	PED	NR	
Zhou *et al*[38]	2014	PS	28/11 (39.3%)	Tubridge	NR	
Puffer *et al*[31]	2014	PM	44/24 (54.5%)	PED, Silk, Surpass	NR	Overlap with PUFS/Sahlein *et al*.[46]. Data recalculated
Sahlein *et al*[46]	2015	PM	108/39 (36.1%)	PED	Yes	Only patients with initial aneurysm-induced NOS included
Zanaty *et al*[45]	2015	RS	44/12 (27.3%)	PED	NR	
Breu *et al*[49]	2016	RS	28/10 (53.7%)	Silk, PED	NR	Data recalculated
Kim *et al*[53]	2016	RM	45/18 (40%)	PED	NR	
Brown *et al*[54]	2016	RM	45/45 (100%)	PED	NR	Overlap with PUFS/Sahlein *et al*[46]
Miyachi *et al*[64]	2017	RM	24/18 (75%)	PED	No	Data recalculated
Silva *et al*[71]	2018	RS	115/21 (18.3%)	PED	NR	
Oishi *et al*[73]	2018	RS	100/38 (38%)	PED	NR	
Yan *et al*[79]	2019	RS	126/50 (39.7%)	PED	NR	Data recalculated
Wang *et al*[76]	2019	RS	22/22 (100%)	PED	No	Data recalculated
Boulouis *et al*[7]	2021	RM	55/54† (98.2%)	PED, Silk, p64, Derivo, Surpass	No	Raw data access
Fujii *et al*[93]	2022	RS	112/29 (25.9%)	PED	NR	Potential overlap with Oishi *et al*[73]
Xu *et al*[95]	2022	RS	189/29 (15.3%)	PED	Yes	
Lee *et al*[94]	2022	RS	49/28 (57.1%)	NR	NR	

*NOS=neuro-ophthalmological symptoms induced by internal carotid artery aneurysm, treated with flow diversion.
†One patient treated with parent vessel occlusion excluded from the original publication.[107]
F/U, follow-up; NR, not reported; PED, Pipeline embolization device; PM, prospective multicenter; PS, prospective single-center; RM, retrospective multi-center; RS, retrospective single-center.

applying random-effects analysis. We performed an additional random-effect meta-regression, studying the effect of mean/median patient age, length of follow-up, and study size as moderators on the effect size of complete NOS recovery and improvement using SPSS Statistics 28 (IBM, Armonk, USA).

RESULTS

Study inclusion

Literature search was performed on March 21, 2022. After removal of duplicates and screening of titles and abstracts, we sought for the original articles of 82 publications.[7 13–93] After completion of literature review and data extraction and before closing the database, the literature search was repeated on PubMed only on May 22, 2022, using the above-mentioned search string to identify additional potentially eligible articles. Two papers published in the meantime were identified.[94 95] Four papers published in Chinese in Chinese journals could not be retrieved.[61 66 69 70] Thus, 80 papers were screened for eligibility. Detailed information on publication inclusion and exclusion are depicted in online supplemental figure 1 and online supplemental table 1.

Descriptive results

Altogether, 22 studies were included, encompassing 594 patients treated with flow diversion for an unruptured intracranial aneurysm of the ICA and compression-related neuro-ophthalmological symptoms. An overview of the included studies is shown in table 1. Online supplemental table 2 depicts patients demographics and aneurysm characteristics. Data on isolated visual or oculomotor symptoms were extracted for 149 and 293 patients, respectively. All relevant data are shown in the online supplemental material. Dedicated neuro-ophthalmological follow-up protocols were mentioned in three publications only.[37 46 95] Neuro-ophthalmological outcomes are depicted in table 2 and in online supplemental tables 3 and 4. Online supplemental table 5 summarizes the neurological complications and anatomical results.

Pooled proportions

Random-effect modeling analysis of NOS (figure 1) showed pooled rates of 47.4% (95% CI 35.0% to 60.1%) for complete recovery, 74.5% (95% CI 67.9% to 80.2%) for improvement, 7.1% (95% CI 3.3% to 14.7%) for transient, and 4.9% (95% CI 3.2% to 7.4%) for permanent symptom worsening. For all parameters except permanent worsening (I^2=0%, p=0.8), significant moderate to substantial study heterogeneity (I^2 between 58% and 79%) was detected (see figure 1). Visual inspection of funnel plots (online supplemental figure 2) and results of Egger's test revealed significant asymmetry for the parameters improvement (p=0.03, online supplemental figure 2B), transient (p<0.0001, online supplemental figure 2C) and

Table 2 Overall neuro-ophthalmological outcomes

Study	Symptom onset to treatment (mean±SD)	Patients with NOS* and F/U	NOS F/U (mean±SD)	Complete recovery	Partial recovery	Improvement (complete and partial recovery)	No change	Transient worsening	Permanent worsening
Yu *et al*[22]	NR	13	3.5 months (median)	10/13 (76.9%)	0 (0%)	10/13 (76.9%)	3/13 (23.1%)	0/13 (0%)	0 (0%)
Szikora *et al*[28]	NR	16	NR	10/16 (62.5%)	5/16 (31.3%)	15/16 (93.8%)	0/16 (0%)	3/16 (18.8%)	1/16 (6.3%)
O'Kelly *et al*[26]	NR	27	NR	12/27 (44.4%)	6/27 (22.2%)	18/27 (66.7%)	9/27 (33.3)	2/27 (7.4%)	0/27 (0%)
Moon *et al*[35]	50.4 weeks (mean)	19	9.7±6.3 months	3/19 (15.8%)	11/19 (57.9%)	14/19 (73.7%)	5/19 (26.3%)	2/19/10.5%)	0/19 (0%)
Tanweer *et al*[37]	NR	19	NR	NR	NR	16/19 (84.2%)	3/19 (15.8%)	0/19 (0%)	0/19/0%)
Zanaty *et al*[34]	NR	51	NR	36/51 (70.6%)	11/51 (21.6%)	47/51 (92.2%)	4/51 (7.8%)	0/51 (0%)	0/51 (0%)
Zhou *et al*[38]	NR	11	NR	4/11 (36.4%)	4/11 (36.4%)	8/11 (72.7%)	3/11 (27.3%)	2/11 (18.2%)	0/11 (0%)
Puffer *et al*[31]	NR	20	10.3±7.6 months	18/20 (90%)	0/20 (0%)	18/20 (90%)	2/20 (10%)	2/20 (10%)	0/20 (0%)
Sahlein *et al*[46]	NR	39	6 months	2/39 (5.1%)	22/39 (56.4%)	24/39 (61.5%)	13/39 (33.3%)	0/39 (0%)	2/39 (5.1%)
Zanaty *et al*[45]	NR	12	NR	9/12 (75%)	3/12 (25%)	12/12 (100%)	0/12 (0%)	0/12 (0%)	0/12 (0%)
Breu *et al*[49]	NR	9	NR	NR	NR	6/9 (66.7%)	3/9 (33.3%)	0/9 (0%)	0/9 (0%)
Kim *et al*[53]	NR	18	NR	NR	NR	15/18 (83.3%)	3/18 (16.7%)	15/18 (83.3%)	0/18 (0%)
Brown *et al*[54]	11 within 4 weeks, 27 beyond	45	8.4 months	19/45 (42.2%)	11/45 (24.4%)	30/45 (66.6%)	14/45 (31.1%)	0/45 (0%)	1/45 (2.2%)
Miyachi *et al*[64]	NR	18	3–6 months	6/18 (33.3%)	10/18 (55.6%)	16/18 (88.9%)	2/18 (11.1%)	8/18 (44.4%)	0/18 (0%)
Silva *et al*[71]	NR	15	NR	NR	NR	14/15 (93.3%)	1/15 (6.7%)	0/15 (0%)	0/15 (0%)
Oishi *et al*[73]	NR	38	13.5 months	NR	NR	18/38 (47.4%)	17/38 (44.7%)	3/38 (7.9%)	0/38 (0%)
Yan *et al*[79]	NR	50	6–33 months	31/50 (62%)	12/50 (24%)	43/50 (86%)	NR	NR	NR
Wang *et al*[76]	11 within 4 weeks, 11 beyond	21	25.5±1.7 months	6/21 (28.6%)	6/21 (28.6%)	12/21 (57.1%)	5/21 (23.8%)	0/21 (0%)	4/21 (19%)
Boulouis *et al*[7]	16.2±7.6 weeks	54	13.2±10.4 months	19/54 (35.2%)	18/54 (33.3%)	37/54 (68.5%)	10/54 (18.5%)	0/54 (0%)	3/54 (5.6%)
Fujii *et al*[93]	NR	29	36 months	NR	NR	20/29 (69%)	7/29 (24.1%)	0/29 (0%)	2/29 (6.9%)
Xu *et al*[95]	8 weeks (median)	26	NR	NR	NR	20/26 (76.9%)	6/26 (23.1%)	0/26 (0%)	0/26 (0%)
Lee *et al*[94]	NR	28	NR	NR	NR	15/28 (53.6%)	NR	NR	NR

*NOS=neuro-ophthalmological symptoms induced by internal carotid artery aneurysm, treated with flow diversion.
F/U, follow-up; NR, not reported.



Figure 1 Forest plots for the proportions of complete recovery (A), improvement (B), transient (C), and permanent worsening (D).

permanent worsening (p<0.0001, online supplemental figure 2D). No significant asymmetry was observed for complete recovery (online supplemental figure 2A; p=0.91).

Pooled rates of complete recovery and improvement in patients with isolated visual symptoms (figure 2A,B) were 30.6% (95% CI 12.5% to 57.7%) and 56.6% (95% CI 42.3% to 69.9%), respectively. Isolated oculomotor symptoms (figure 2C,D) recovered completely in 47.8% (95% CI 29.9 to 66.3) and improved in 78% (95% CI 69.2 to 84.9). All parameters demonstrated significant moderate to substantial heterogeneity (I^2 between 44% and 78%, p<0.05). Funnel plots (online supplemental figure 3) and Egger's test revealed publication bias only for the



Figure 2 Forest plots for the proportions of complete visual recovery (A) and improvement (B), and complete oculomotor recovery (C) and improvement (D).



Figure 3 Forest plots for the proportions of morbidity (A) and mortality (B).

parameter oculomotor improvement (p=0.006; other p values >0.05).

The pooled estimate of complete aneurysm occlusion at last follow-up was 68.6% (95% CI 58.8% to 77%). No significant heterogeneity or publication asymmetry was observed (Egger's test p=0.12; online supplemental figure 4).

The pooled proportions of morbidity and mortality were 5% (95% CI 2.8% to 9%) and 3.9% (95% CI 2% to 7.5%), as shown in figure 3. Neither significant heterogeneity nor asymmetry (online supplemental figure 5; Egger's test p>0.05) were detected.

Early versus late treatment

For a subset of 110 patients, information on time lapse from symptom onset to treatment were available. Random-effects analysis showed an increased likelihood of symptom improvement when treatment was performed early (ie, within 1 month) after symptom onset (OR=11.22, 95% CI 3.9% to 32.5%). The respective Forest plot is shown in figure 4, no relevant heterogeneity was detected.

Influence of patient age, length of follow-up, and study size on neuro-ophthalmological outcome

Meta-regression revealed a significant effect of patient age on improvement of NOS (p=0.006; R^2=100%) and a non-significant association with complete NOS recovery (p=0.126; R^2=61.6%), as is shown in online supplemental figure 6A,B. No relevant effect on NOS complete recovery and improvement was detected when using the length of follow-up (in months) and the study size as moderators (online supplemental figure 6C–F).

DISCUSSION

Our meta-analysis of 594 patients treated with FD for ICA aneurysm with compressive NOS is the first to give a global overview on the literature for this specific patient population and treatment technique. Forty-eight percent of the patients treated with flow diversion recovered completely from their initial deficit and almost 75% showed improvement of compressive symptoms. Transient and permanent worsening occurred in 7.1% and 4.9% of patients, respectively. Complications were not uncommon, however, with morbidity occurring in 5% and mortality in 3.9% of patients. Complete recovery and improvement were less common in patients with isolated visual symptoms (30.6% and 56.6%), than in those with with isolated oculomotor symptoms (47.8% and 78%). Early treatment of symptomatic aneurysms with compressive symptoms seems to be essential: our analysis suggests that the likelihood of symptom improvement increases more than 10-fold if treatment is performed within the first month.

Alternative treatment methods differ, depending on the location of the aneurysm. Extradural aneurysms have historically been treated mostly with PAO only or in conjunction with an extracranial–intracranial bypass surgery in cases of a negative test occlusion. A meta-analysis from 2015 found an improvement in mass effect in 83% of patients treated with PAO only, which is comparable to the present data.[96] Also, the rates of morbidity and mortality of PAO only (7% and 4%) were comparable with the current data for flow diversion but they increased to 11% and 7% when an additional bypass was needed for PAO.[96] Interestingly, the authors found also that selective coil embolization of the culprit aneurysm leads to symptom improvement in 72% but is associated with a high re-treatment rate for 18%, given that large and giant aneurysms often recur after coil embolization.[97] In our interpretation of the data, selective coiling of compressive extradural aneurysms is not an expedient treatment, as it is most probably not durable and aneurysm recurrence remains in many instances only a question of time. But also, in modern times PAO remains a valuable option, particularly if the vessel can be sacrificed without prior bypass surgery. The increased odds of complications with this surgical procedure may, however, favor flow diversion for patients for whom an occlusion test has failed.

Compressive intradural aneurysms, arising on the distal intracranial ICA were in the past mainly treated with microsurgical clipping or selective coil embolization. A meta-analysis of the treatment of paraclinoid aneurysms[98] found that vision improved in 58% of patients after clipping and 49% after coiling. Vision worsened in 11% of patients after clipping and 9% after coiling. Interestingly, 71% vision improvement and 5% worsening were described in that analysis for FD. For compressive aneurysms of the posterior communicating artery segment, microsurgical



Figure 4 Forest plots for the effect of early (within 1 month) and delayed (>1 month) treatment on symptom improvement.

clipping is an even more well-studied and valid option. Meta-analyses conducted for ruptured and unruptured aneurysms found higher rates of symptom recovery/improvement in patients treated surgically compared with intrasaccular coiling.[3 99] Additionally, a large proportion of posterior communicating artery aneurysms develop NOS in the setting of rupture and are thus not eligible for flow diversion.[100] The observation that the odds of NOS improvement and possibly also of complete recovery tend to increase with patient age is surprising, as nerve regeneration is known to be delayed and less effective in the aging individual.[101] Accordingly, in a recent study increasing age was associated with incomplete recovery, and patients recovering completely were significantly younger than those who showed incomplete recovery only.[7]

The present meta-analysis underpins the importance of timely treatment, as the likelihood of symptom improvement increases more than 10-fold if treatment is performed within the first month. Prompt diagnosis and treatment of these patients is thus paramount and delays should be avoided, also when the aneurysm is unruptured.

The pooled rates of morbidity and mortality were 5% and 3.9%, respectively, which is higher than the findings of PUFS (morbidity/mortality rate of 5.6%),[102] but comparable to the International Retrospective Study of the Pipeline Embolization Device (IntrePED). In that registry, neurologic morbidity/mortality was observed in 9.2% of patients with unruptured aneurysms of the ICA measuring more than 10 mm.[103] As recent studies have shown that the risk of morbidity/mortality increases more than threefold per decade of age,[7 104] we conclude that treatment with FD for compressive ICA aneurysms in elderly patients should be considered only after careful consideration of the risk–benefit ratio. The fact that chances of complete symptom recovery may decrease with increasing age, fusiform aneurysm morphology, and a longer delay between the onset of ocular symptoms and endovascular treatment should be taken into account. This is important in particular for extradural aneurysms, which pose a negligible statistical risk of hemorrhage in the elderly patient.[105]

The pooled rate of complete occlusion (68.6%) is comparable to published data in the literature. While complete occlusion was observed in 86.8% in PUFS after 12 months,[102] which should be seen as highly selected patient sample, complete occlusion at 12 months was described in 75.8% of aneurysms in a single-centre series of 1000 aneurysms treated with the PED.[106]

Our meta-analysis has some limitations. It is inherently flawed by the fact that many included publications are retrospective, often single-center case series. Moreover, earlier series on FD (for example[34 35 37 45]) bear the risk of overlap with the subset analysis of patients with NOS in the PUFS study by Sahlein *et al*[46]; some studies explicitly stated that patients had been at least partly included in PUFS.[28 31 54] A small number of double inclusions in this meta-analysis must thus be assumed. Another limitation is that in many studies, no specific demographic and procedural details were given for the subset of patients with NOS, as they were described as a fraction of a larger study on FD use for ICA aneurysms. Overall, the extracted data are characterized by substantial study heterogeneity and signs of publication bias and only in a minority of publications was specialized neuro-ophthalmological follow-up carried out.

CONCLUSION

Flow diversion for compressive ICA aneurysms with NOS leads to recovery or improvement of compressive symptoms in a large proportion of patients and is a valuable treatment strategy—in particular, if sacrifice of the parent vessel is not possible. However, it is associated with significant rates of morbidity and mortality, and transient or permanent NOS worsening is not uncommon. Early detection and treatment of compressive aneurysms is paramount, as treatment within the first month from symptom onset increases the likelihood of symptom improvement more than 10-fold. The present literature is characterized by significant heterogeneity and publication bias and only a minority of publications specified dedicated neuro-ophthalmological follow-up investigations. Controlled data should thus be obtained in the future, potentially also providing solid evidence on which treatment should be chosen for which patient.

Correction notice This article has been corrected since it was first published. The open access licence has been updated to CC BY. 17th May 2023.

Twitter Daniel P O Kaiser @daniel_kaiserMD

Contributors DPOK: Acquisition of data, data analysis, critical review of manuscript, approval of manuscript. AC, JL: Critical review of manuscript, approval of manuscript. MG: Acquisition of data, data analysis, drafting of manuscript, critical review of manuscript, approval of manuscript, guarantor of the study.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests DPOK: Received stents from Phenox for research purposes and funding from the Else Körner Fresenius Center of Digital Health and the Joachim Herz Foundation; has a non-financial research agreement with Brainomix; serves as board member of the German Society of Neuroradiology (DGNR). MG: Consultancy contract with Phenox; proctoring contract with MicroVention; member of the clinical event committee for a study on a flow diverter, sponsored by Microvention; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events by Phenox; received stents from Phenox for research purposes; received funding from the Else Körner Fresenius Center of Digital Health.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

REFERENCES

1 Micieli JA, Newman NJ, Barrow DL, *et al*. Intracranial aneurysms of neuro-ophthalmologic relevance. *J Neuroophthalmol* 2017;37:421–39.
2 van Rooij WJ, Sluzewski M. Unruptured large and giant carotid artery aneurysms presenting with cranial nerve palsy: comparison of clinical recovery after selective aneurysm coiling and therapeutic carotid artery occlusion. *AJNR Am J Neuroradiol* 2008;29:997–1002.
3 Güresir E, Schuss P, Setzer M, *et al*. Posterior communicating artery aneurysm-related oculomotor nerve palsy: influence of surgical and endovascular treatment on recovery: single-center series and systematic review. *Neurosurgery* 2011;68:1527–34.
4 Hassan T, Hamimi A. Successful endovascular management of brain aneurysms presenting with mass effect and cranial nerve palsy. *Neurosurg Rev* 2013;36:87–97.
5 Dodier P, Wang W-T, Hosmann A. Combined standard bypass and parent artery occlusion for management of giant and complex internal carotid artery aneurysms. *J Neurointerv Surg* 2022;14:593–8.

6 Szikora I, Marosfői M, Salomváry B. Resolution of mass effect and compression symptoms following endoluminal flow diversion for the treatment of intracranial aneurysms. *AJNR Am J Neuroradiol* 2013;34:935–9.
7 Boulouis G, Soize S, Maus V. Flow diversion for internal carotid artery aneurysms with compressive neuro-ophthalmologic symptoms: clinical and anatomical results in an international multicenter study. *J NeuroIntervent Surg* 2021.
8 Raymond J, Guilbert F, Weill A, *et al*. Long-term angiographic recurrences after selective endovascular treatment of aneurysms with detachable coils. *Stroke* 2003;34:1398–403.
9 O'kelly CJ, Krings T, Fiorella D, *et al*. A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. *Interv Neuroradiol* 2010;16:133–7.
10 Viechtbauer W. Conducting meta-analyses in *R* with the metafor package. *J Stat Softw* 2010;36.
11 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019;22:153–60.
12 Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration 2020.
13 Szikora I, Berentei Z, Kulcsar Z, *et al*. Treatment of intracranial aneurysms by functional reconstruction of the parent artery: the Budapest experience with the pipeline embolization device. *AJNR Am J Neuroradiol* 2010;31:1139–47.
14 Lubicz B, Collignon L, Raphaeli G, *et al*. Flow-diverter stent for the endovascular treatment of intracranial aneurysms: a prospective study in 29 patients with 34 aneurysms. *Stroke* 2010;41:2247–53.
15 Nelson PK, Lylyk P, Szikora I, *et al*. The pipeline embolization device for the intracranial treatment of aneurysms trial. *AJNR Am J Neuroradiol* 2011;32:34–40.
16 Leonardi M, Cirillo L, Toni F, *et al*. Treatment of intracranial aneurysms using flow-diverting silk stents (BALT): a single centre experience. *Interv Neuroradiol* 2011;17:306–15.
17 Berge J, Biondi A, Machi P, *et al*. Flow-diverter silk stent for the treatment of intracranial aneurysms: 1-year follow-up in a multicenter study. *AJNR Am J Neuroradiol* 2012;33:1150–5.
18 Briganti F, Napoli M, Tortora F, *et al*. Italian multicenter experience with flow-diverter devices for intracranial unruptured aneurysm treatment with periprocedural complications--a retrospective data analysis. *Neuroradiology* 2012;54:1145–52.
19 Puffer RC, Kallmes DF, Cloft HJ, *et al*. Patency of the ophthalmic artery after flow diversion treatment of paraclinoid aneurysms. *J Neurosurg* 2012;116:892–6.
20 Kan P, Siddiqui AH, Veznedaroglu E, *et al*. Early postmarket results after treatment of intracranial aneurysms with the pipeline embolization device: a U.S. multicenter experience. *Neurosurgery* 2012;71:1080–7.
21 Lanzino G, Crobeddu E, Cloft HJ, *et al*. Efficacy and safety of flow diversion for paraclinoid aneurysms: a matched-pair analysis compared with standard endovascular approaches. *AJNR Am J Neuroradiol* 2012;33:2158–61.
22 Yu SC-H, Kwok C-K, Cheng P-W, *et al*. Intracranial aneurysms: midterm outcome of pipeline embolization device--a prospective study in 143 patients with 178 aneurysms. *Radiology* 2012;265:893–901.
23 Chalouhi N, Tjoumakaris S, Starke RM, *et al*. Comparison of flow diversion and coiling in large unruptured intracranial saccular aneurysms. *Stroke* 2013;44:2150–4.
24 De Vries J, Boogaarts J, Van Norden A, *et al*. New generation of flow diverter (Surpass) for unruptured intracranial aneurysms: a prospective single-center study in 37 patients. *Stroke* 2013;44:1567–77.
25 Toma AK, Robertson F, Wong K, *et al*. Early single centre experience of flow diverting stents for the treatment of cerebral aneurysms. *Br J Neurosurg* 2013;27:622–8.
26 O'Kelly CJ, Spears J, Chow M, *et al*. Canadian experience with the pipeline embolization device for repair of unruptured intracranial aneurysms. *AJNR Am J Neuroradiol* 2013;34:381–7.
27 Colby GP, Lin L-M, Gomez JF, *et al*. Immediate procedural outcomes in 35 consecutive pipeline embolization cases: a single-center, single-user experience. *J Neurointerv Surg* 2013;5:237–46.
28 Szikora I, Marosfoi M, Salomváry B, *et al*. Resolution of mass effect and compression symptoms following endoluminal flow diversion for the treatment of intracranial aneurysms. *AJNR Am J Neuroradiol* 2013;34:935–9.
29 Malatesta E, Nuzzi NP, Divenuto I, *et al*. Endovascular treatment of intracranial aneurysms with flow-diverter stents: preliminary single-centre experience. *Radiol Med* 2013;118:971–83.
30 Moon K, Albuquerque FC, Ducruet AF, *et al*. Treatment of ophthalmic segment carotid aneurysms using the pipeline embolization device: clinical and angiographic follow-up. *Neurol Res* 2014;36:344–50.
31 Puffer RC, Piano M, Lanzino G, *et al*. Treatment of cavernous sinus aneurysms with flow diversion: results in 44 patients. *AJNR Am J Neuroradiol* 2014;35:948–51.
32 Heller RS, Lawlor CM, Hedges TR, *et al*. Neuro-ophthalmic effects of stenting across the ophthalmic artery origin in the treatment of intracranial aneurysms. *J Neurosurg* 2014;121:18–23.
33 Chalouhi N, Tjoumakaris S, Phillips JLH, *et al*. A single pipeline embolization device is sufficient for treatment of intracranial aneurysms. *AJNR Am J Neuroradiol* 2014;35:1562–6.
34 Zanaty M, Chalouhi N, Starke RM, *et al*. Flow diversion versus conventional treatment for carotid cavernous aneurysms. *Stroke* 2014;45:2656–61.
35 Moon K, Albuquerque FC, Ducruet AF, *et al*. Resolution of cranial neuropathies following treatment of intracranial aneurysms with the pipeline embolization device. *J Neurosurg* 2014;121:1085–92.
36 Buyukkaya R, Kocaeli H, Yildirim N, *et al*. Treatment of complex intracranial aneurysms using flow-diverting silk® stents. An analysis of 32 consecutive patients. *Interv Neuroradiol* 2014;20:729–35.
37 Tanweer O, Raz E, Brunswick A, *et al*. Cavernous carotid aneurysms in the era of flow diversion: a need to revisit treatment paradigms. *AJNR Am J Neuroradiol* 2014;35:2334–40.
38 Zhou Y, Yang P-F, Fang Y-B, *et al*. A novel flow-diverting device (Tubridge) for the treatment of 28 large or giant intracranial aneurysms: a single-center experience. *AJNR Am J Neuroradiol* 2014;35:2326–33.
39 Alghamdi F, Morais R, Scillia P, *et al*. The silk flow-diverter stent for endovascular treatment of intracranial aneurysms. *Expert Rev Med Devices* 2015;12:753–62.
40 Fischer S, Aguilar-Pérez M, Henkes E, *et al*. Initial experience with p64: a novel mechanically detachable flow diverter for the treatment of intracranial saccular sidewall aneurysms. *AJNR Am J Neuroradiol* 2015;36:2082–9.
41 Oh S-Y, Lee KS, Kim B-S, *et al*. Management strategy of surgical and endovascular treatment of unruptured paraclinoid aneurysms based on the location of aneurysms. *Clin Neurol Neurosurg* 2015;128:72–7.
42 Shimizu T, Naito I, Aihara M, *et al*. Visual outcomes of endovascular and microsurgical treatment for large or giant paraclinoid aneurysms. *Acta Neurochir* 2015;157:13–20.
43 Wakhloo AK, Lylyk P, de Vries J, *et al*. Surpass flow diverter in the treatment of intracranial aneurysms: a prospective multicenter study. *AJNR Am J Neuroradiol* 2015;36:98–107.
44 Rouchaud A, Leclerc O, Benayoun Y, *et al*. Visual outcomes with flow-diverter stents covering the ophthalmic artery for treatment of internal carotid artery aneurysms. *AJNR Am J Neuroradiol* 2015;36:330–6.
45 Zanaty M, Chalouhi N, Barros G, *et al*. Flow-diversion for ophthalmic segment aneurysms. *Neurosurgery* 2015;76:286–9. discussion 289-290.
46 Sahlein DH, Fouladvand M, Becske T, *et al*. Neuroophthalmological outcomes associated with use of the pipeline embolization device: analysis of the PUFS trial results. *J Neurosurg* 2015;123:897–905.
47 Di Maria F, Pistocchi S, Clarençon F, *et al*. Flow diversion versus standard endovascular techniques for the treatment of unruptured carotid-ophthalmic aneurysms. *AJNR Am J Neuroradiol* 2015;36:2325–30.
48 Zhu Y, Pan J, Shen J, *et al*. Clinical and radiological outcomes after treatment of unruptured paraophthalmic internal carotid artery aneurysms: a comparative and pooled analysis of single-center experiences. *World Neurosurg* 2015;84:1726–38.
49 Breu A-K, Hauser T-K, Ebner FH, *et al*. Morphologic and clinical outcome of intracranial aneurysms after treatment using flow diverter devices: mid-term follow-up. *Radiol Res Pract* 2016;2016:2187275.
50 Burrows AM, Brinjikji W, Puffer RC, *et al*. Flow diversion for ophthalmic artery aneurysms. *AJNR Am J Neuroradiol* 2016;37:1866–9.
51 Kallmes DF, Brinjikji W, Boccardi E, *et al*. Aneurysm study of pipeline in an observational registry (ASPIRe). *Interv Neurol* 2016;5:89–99.
52 Kaya T, Daglioglu E, Gurkas E, *et al*. Silk device for the treatment of intracranial aneurysms, part 2: factors related to clinical and angiographic outcome. *Turk Neurosurg* 2016;26:533–7.
53 Kim BM, Shin YS, Baik MW, *et al*. Pipeline embolization device for large/giant or fusiform aneurysms: an initial multi-center experience in Korea. *Neurointervention* 2016;11:10–17.
54 Brown BL, Lopes D, Miller DA, *et al*. The fate of cranial neuropathy after flow diversion for carotid aneurysms. *J Neurosurg* 2016;124:1107–13.
55 Durst CR, Starke RM, Clopton D, *et al*. Endovascular treatment of ophthalmic artery aneurysms: ophthalmic artery patency following flow diversion versus coil embolization. *J Neurointerv Surg* 2016;8:919–22.
56 Jevsek M, Mounayer C, Seruga T. Endovascular treatment of unruptured aneurysms of cavernous and ophthalmic segment of internal carotid artery with flow diverter device pipeline. *Radiol Oncol* 2016;50:378–84.
57 Becske T, Brinjikji W, Potts MB, *et al*. Long-term clinical and angiographic outcomes following pipeline embolization device treatment of complex internal carotid artery aneurysms: five-year results of the pipeline for uncoilable or failed aneurysms trial. *Neurosurgery* 2017;80:40–8.
58 Bhogal P, Hellstern V, Bäzner H, *et al*. The use of flow diverting stents to treat para-ophthalmic aneurysms. *Front Neurol* 2017;8:381.
59 Miyachi S, Ohnishi H, Hiramatsu R, *et al*. Innovations in endovascular treatment strategies for large carotid cavernous aneurysms-the safety and efficacy of a flow diverter. *J Stroke Cerebrovasc Dis* 2017;26:1071–80.
60 Peschillo S, Caporlingua A, Resta MC, *et al*. Endovascular treatment of large and giant carotid aneurysms with flow-diverter stents alone or in combination with coils: a multicenter experience and long-term follow-up. *Oper Neurosurg* 2017;13:492–502.
61 Xiao X, Mao G, Zhu J. Short-term follow-up for unruptured wide-necked intracranial aneurysms treated with pipeline embolization device. *Chinese Journal of Cerebrovascular Diseases* 2017;14:628–32.

62 Briganti F, Leone G, Ugga L, *et al*. Mid-term and long-term follow-up of intracranial aneurysms treated by the p64 flow modulation device: a multicenter experience. *J Neurointerv Surg* 2017;9:70–6.
63 Griessenauer CJ, Piske RL, Baccin CE, *et al*. Flow diverters for treatment of 160 ophthalmic segment aneurysms: evaluation of safety and efficacy in a multicenter cohort. *Neurosurgery* 2017;80:726–32.
64 Miyachi S, Hiramatsu R, Ohnishi H, *et al*. Usefulness of the pipeline embolic device for large and giant carotid cavernous aneurysms. *Neurointervention* 2017;12:83–90.
65 Byvaltsev VA, Makhambetov YT, Stepanov IA, *et al*. Outcome analysis of the flow diversion with pipeline embolization device for the surgical treatment of unruptured large and giant paraclinoid carotid aneurysms. *Annals RAMS* 2018;73:16–22.
66 Jinguei L, Guilin L, Shengpan C. Roles of pipeline embolization device in combination with coils in the treatment of large and giant unruptured internal carotid artery aneurysms. *Chinese Journal of Cerebrovascular Diseases* 2018;15:4–9.
67 Killer-Oberpfalzer M, Kocer N, Griessenauer CJ, *et al*. European multicenter study for the evaluation of a dual-layer flow-diverting stent for treatment of wide-neck intracranial aneurysms: the European flow-redirection intraluminal device study. *AJNR Am J Neuroradiol* 2018;39:841–7.
68 ReXiaTi N, AiKeReMu R, KaDeEr K, *et al*. Short-term efficacy of pipeline embolization device for treating complex intracranial aneurysms. *Biomed Mater Eng* 2018;29:137–46.
69 Too L, Shijie N, Zong Z. The application or pipeline embolization device in treating intracranial aneurysms located between cavernous sinus segment and ophthalmic artery segment. *Journal of Interventional Radiology* 2018;27:1127–32.
70 Yanling G, Fangqiang P, Shubin T. Medium and long-term effects of pipeline embolization device for the treatment of large and giant intracranial anterior circulation aneurysms. *Chinese Journal of Cerebrovascular Diseases* 2018;15:16–20.
71 Silva MA, See AP, Khandelwal P, *et al*. Comparison of flow diversion with clipping and coiling for the treatment of paraclinoid aneurysms in 115 patients. *J Neurosurg* 2018:1–8.
72 Pierot L, Spelle L, Berge J, *et al*. Feasibility, complications, morbidity, and mortality results at 6 months for aneurysm treatment with the flow re-direction endoluminal device: report of SAFE study. *J Neurointerv Surg* 2018;10:765-770.
73 Oishi H, Teranishi K, Yatomi K, *et al*. Flow diverter therapy using a pipeline embolization device for 100 unruptured large and giant internal carotid artery aneurysms in a single center in a Japanese population. *Neurol Med Chir* 2018;58:461–7.
74 Griessenauer CJ, Thomas AJ, Enriquez-Marulanda A, *et al*. Comparison of pipeline embolization device and flow re-direction endoluminal device flow diverters for internal carotid artery aneurysms: a propensity score-matched cohort study. *Neurosurgery* 2019;85:E249–55.
75 Oğuz Şükrü, Tabakci Ömer Naci, Uysal E, *et al*. Pipeline flex embolization device (PED flex) for the treatment of intracranial aneurysms: periprocedural outcomes and first-year angiographic results. *Turk J Med Sci* 2019;49:1640–6.
76 Wang Z, Tian Z, Li W, *et al*. Variation of mass effect after using a flow diverter with adjunctive coil embolization for symptomatic unruptured large and giant intracranial aneurysms. *Front Neurol* 2019;10:1191.
77 Kühn AL, Kan P, Srinivasan V, *et al*. Flow diverter for endovascular treatment of intracranial mirror segment internal carotid artery aneurysms. *Interv Neuroradiol* 2019;25:4–11.
78 Pierot L, Spelle L, Berge J, *et al*. SAFE study (Safety and efficacy Analysis of FRED Embolic device in aneurysm treatment): 1-year clinical and anatomical results. *J Neurointerv Surg* 2019;11:184–9.
79 Yan P, Zhang Y, Liang F, *et al*. Comparison of safety and effectiveness of endovascular treatments for unruptured intracranial large or giant aneurysms in internal carotid artery. *World Neurosurg* 2019;125:e385–91.
80 Meyers PM, Coon AL, Kan PT. SCENT Trial: one-year outcomes. *Stroke* 2019;50:1473–9.
81 Sweid A, Rahm SP, Das S, *et al*. Safety and efficacy of bilateral flow diversion for treatment of anterior circulation cerebral aneurysms. *World Neurosurg* 2019;130:e1116–21.
82 Daglioglu E, Akmangit I, Acik V, *et al*. The experience of the DerivoÂ® embolisation device in intracranial aneurysms. *Turk Neurosurg* 2020;30:30–7.
83 Piano M, Valvassori L, Lozupone E, *et al*. FRED Italian registry: a multicenter experience with the flow re-direction endoluminal device for intracranial aneurysms. *J Neurosurg* 2020;133:174–81.
84 Binh NT, Luu VD, Thong PM, *et al*. Flow diverter stent for treatment of cerebral aneurysms: a report of 130 patients with 134 aneurysms. *Heliyon* 2020;6:e03356.
85 Foreman PM, Salem MM, Griessenauer CJ, *et al*. Flow diversion for treatment of partially thrombosed aneurysms: a multicenter cohort. *World Neurosurg* 2020;135:e164–73.
86 Lv X, Yu J, Liao T, *et al*. Unruptured giant intracavernous aneurysms untolerate internal carotid artery occlusion test: untreated and treated with flow-diversion. *Neuroradiol J* 2020;33:105–11.
87 Nurminen V, Raj R, Numminen J, *et al*. Flow diversion for internal carotid artery aneurysms: impact of complex aneurysm features and overview of outcome. *Clin Neurol Neurosurg* 2020;193:105782.
88 Link TW, Carnevale JA, Goldberg JL, *et al*. Multiple pipeline embolization devices improves aneurysm occlusion without increasing morbidity: a single center experience of 140 cases. *J Clin Neurosci* 2021;86:129–35.
89 Kunert P, Wójtowicz K, Żyłkowski J, *et al*. Flow-diverting devices in the treatment of unruptured ophthalmic segment aneurysms at a mean clinical follow-up of 5 years. *Sci Rep* 2021;11:9206.
90 Catapano JS, Koester SW, Srinivasan VM, *et al*. A comparative propensity-adjusted analysis of microsurgical versus endovascular treatment of unruptured ophthalmic artery aneurysms. *J Neurosurg* 2021:1–6.
91 Lee H, Marotta TR, Spears J, *et al*. Endovascular treatment of cavernous carotid artery aneurysms: a 10-year, single-center experience. *Neuroradiol J* 2021;34:568–74.
92 Fehrenbach MK, Dietel E, Wende T, *et al*. Management of cavernous carotid artery aneurysms: a retrospective single-center experience. *Brain Sci* 2022;12. doi:10.3390/brainsci12030330. [Epub ahead of print: 28 02 2022].
93 Fujii T, Teranishi K, Yatomi K, *et al*. Long-term follow-up results after flow diverter therapy using the pipeline embolization device for large or giant unruptured internal carotid artery aneurysms: single-center retrospective analysis in the Japanese population. *Neurol Med Chir* 2022;62:19–27.
94 Lee JK, Choi JH, Kim B-S, *et al*. Recovery from cranial nerve symptoms after flow diversion without coiling for unruptured very large and giant ICA aneurysms. *AJNR Am J Neuroradiol* 2022:ajnr;ajnr.A7498v1.
95 Xu C, Wu P, Sun B. Incomplete occlusion and visual symptoms of peri-ophthalmic aneurysm after treatment with a pipeline embolization device: a multi-center cohort study. *Acta Neurochir* 2022;130.
96 Turfe ZA, Brinjikji W, Murad MH, *et al*. Endovascular coiling versus parent artery occlusion for treatment of cavernous carotid aneurysms: a meta-analysis. *J Neurointerv Surg* 2015;7:250–5.
97 Choi JH, Lee KS, Kim B-S, *et al*. Treatment outcomes of large and giant intracranial aneurysms according to various treatment modalities. *Acta Neurochir* 2020;162:2745–52.
98 Silva MA, See AP, Dasenbrock HH, *et al*. Vision outcomes in patients with paraclinoid aneurysms treated with clipping, coiling, or flow diversion: a systematic review and meta-analysis. *Neurosurg Focus* 2017;42:E15.
99 Zheng F, Chen X, Zhou J, *et al*. Clipping versus coiling in the treatment of oculomotor nerve palsy induced by unruptured posterior communicating artery aneurysms: a meta-analysis of cohort studies. *Clin Neurol Neurosurg* 2021;206:106689.
100 Gaberel T, Borha A, di Palma C, *et al*. Clipping versus coiling in the management of posterior communicating artery aneurysms with third nerve palsy: a systematic review and meta-analysis. *World Neurosurg* 2016;87:498–506.
101 Verdú E, Ceballos D, Vilches JJ, *et al*. Influence of aging on peripheral nerve function and regeneration. *J Peripher Nerv Syst* 2000;5:191–208.
102 Becske T, Kallmes DF, Saatci I, *et al*. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. *Radiology* 2013;267:858–68.
103 Kallmes DF, Hanel R, Lopes D, *et al*. International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment study. *AJNR Am J Neuroradiol* 2015;36:108–15.
104 Kaiser DPO, Boulouis G, Soize S, *et al*. Flow diversion for ICA aneurysms with compressive neuro-ophthalmologic symptoms: predictors of morbidity, mortality, and incomplete aneurysm occlusion. *AJNR Am J Neuroradiol* 2022;43:998–1003.
105 Kupersmith MJ, Stiebel-Kalish H, Huna-Baron R, *et al*. Cavernous carotid aneurysms rarely cause subarachnoid hemorrhage or major neurologic morbidity. *J Stroke Cerebrovasc Dis* 2002;11:9–14.
106 Lylyk I, Scrivano E, Lundquist J, *et al*. Pipeline embolization devices for the treatment of intracranial aneurysms, single-center registry: long-term angiographic and clinical outcomes from 1000 aneurysms. *Neurosurgery* 2021;89:443:443–9.
107 Gawlitza M, Soize S, Manceau P-F, *et al*. Delayed intra-aneurysmal migration of a flow diverter construct after treatment of a giant aneurysm of the cavernous internal carotid artery. *J Neuroradiol* 2020;47:233–6.

SUPPLEMENTAL MATERIAL

Search algorithm

("Aneurysm"[MeSH] OR "aneurysm"[tiab]) AND ("Carotid Artery, Internal"[MeSH] OR "Ophthalmic Artery"[MeSH] OR "ophthalmic"[tiab] OR "paraclinoid"[tiab] OR "clinoidal"[tiab] OR "superior hypophyseal"[tiab] OR "cavernous"[tiab] OR "petrous"[tiab] OR "visual"[tiab] OR "compressive"[tiab] OR "compression"[tiab] OR "cranial nerve"[tiab]) AND ("flow diversion"[tiab] OR "flow diverter"[tiab] OR "flow diverter"[tiab] OR "flow diverting" OR "Pipeline embolization device" OR Silk OR Fred OR P64 OR Surpass OR "Pipeline flex" OR Tubridge). [tiab] and [MeSH] arguments were removed for literature search on Scopus and Web of Science.

Supplemental Table 1: Study selection

No.	Year	First Author	Journal	DOI	Inclusion	Reason for exclusion
1	2010	Lubicz	Stroke	10.1161/STROKEAHA.110.589911	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
2	2010	Szikora	AJNR. American journal of neuroradiology	10.3174/ajnr.A2023	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
3	2011	Leonardi	Interventional neuroradiology	10.1177/159101991101700305	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
4	2011	Nelson	AJNR. American journal of neuroradiology	10.3174/ajnr.A2421	No	No detailed information on cranial nerve palsies
5	2012	Lanzino	AJNR. American journal of neuroradiology	10.3174/ajnr.A3207	No	No detailed information on cranial nerve palsies
6	2012	Puffer	Journal of neurosurgery	10.3171/2011.11.JNS111612	No	No detailed information on cranial nerve palsies
7	2012	Briganti	Neuroradiology	10.1007/s00234-012-1047-3	No	No detailed information on cranial nerve palsies
8	2012	Berge	American Journal of Neuroradiology	10.3174/ajnr.A2907	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
9	2012	Kan	Neurosurgery	10.1227/NEU.0b013e31827060d9	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
10	2012	Yu	Radiology	10.1148/radiol.12120422	Yes	
11	2013	Malatesta	La Radiologia medica	10.1007/s11547-013-0944-9	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
12	2013	Szikora	AJNR. American journal of neuroradiology	10.3174/ajnr.A3547	Yes	
13	2013	O'Kelly	AJNR. American journal of neuroradiology	10.3174/ajnr.A3224	Yes	
14	2013	Colby	Journal of neurointerventional surgery	10.1136/neurintsurg-2012-010299	No	No detailed information on cranial nerve palsies
15	2013	Toma	British Journal of Neurosurgery	10.3109/02688697.2013.793292	No	No detailed information on cranial nerve palsies
16	2013	Chalouhi	Stroke	10.1161/STROKEAHA.113.001785	No	No detailed information on cranial nerve palsies
17	2013	De Vries	Stroke	10.1161/STROKEAHA.111.000434	No	No detailed information on cranial nerve palsies
18	2014	Buyukkaya	Interventional neuroradiology	10.15274/INR-2014-10070	No	No detailed information on cranial nerve palsies
19	2014	Moon	Journal of neurosurgery	10.3171/2014.7.JNS132677	Yes	
20	2014	Tanweer	AJNR. American journal of neuroradiology	10.3174/ajnr.A4081	Yes	
21	2014	Zanaty	Stroke	10.1161/STROKEAHA.114.006247	Yes	
22	2014	Heller	Journal of neurosurgery	10.3171/2014.3.JNS131493	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
23	2014	Zhou	AJNR. American journal of neuroradiology	10.3174/ajnr.A3925	Yes	
24	2014	Moon	Neurological research	10.1179/1743132814Y.0000000322	No	No detailed information on cranial nerve palsies
25	2014	Puffer	AJNR. American journal of neuroradiology	10.3174/ajnr.A3826	Yes	
26	2014	Chalouhi	AJNR. American journal of neuroradiology	10.3174/ajnr.A3957	No	No detailed information on cranial nerve palsies
27	2015	Di Maria	AJNR. American journal of neuroradiology	10.3174/ajnr.A4437	No	No detailed information on cranial nerve palsies
28	2015	Sahlein	Journal of neurosurgery	10.3171/2014.12.JNS141777	Yes	
29	2015	Zanaty	Neurosurgery	10.1227/NEU.0000000000000607	Yes	
30	2015	Rouchaud	AJNR. American journal of neuroradiology	10.3174/ajnr.A4129	No	Less than 10 patients with cranial nerve palsies
31	2015	Wakhloo	AJNR. American journal of neuroradiology	10.3174/ajnr.A4078		At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
32	2015	Alghamdi	Expert Review of Medical Devices	10.1586/17434440.2015.1093413	No	Review article
33	2015	Fischer	AJNR. American journal of neuroradiology	10.3174/ajnr.A4420	No	No detailed information on cranial nerve palsies
34	2015	Shimizu	Acta neurochirurgica	10.1007/s00701-014-2251-1	No	No flow diverter devices applied
35	2015	Oh	Clinical neurology and neurosurgery	10.1016/j.clineuro.2014.11.008	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
36	2015	Zhu	World neurosurgery	10.1016/j.wneu.2015.07.036	No	Review article
37	2016	Jevsek	Radiology and oncology	10.1515/raon-2016-0049		Less than 10 patients with cranial nerve palsies treated by flow diversion
38	2016	Kaya	Turkish neurosurgery	10.5137/1019-5149.JTN.14760-15.0	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
39	2016	Breu	Radiology research and practice	10.1155/2016/2187275	Yes	
40	2016	Kim	Neurointervention	10.5469/neuroint.2016.11.1.10	Yes	
41	2016	Brown	Journal of neurosurgery	10.3171/2015.4.JNS142790	Yes	
42	2016	Durst	Journal of neurointerventional surgery	10.1136/neurintsurg-2015-011887	No	No detailed information on cranial nerve palsies
43	2016	Burrows	AJNR. American journal of neuroradiology	10.3174/ajnr.A4835	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
44	2016	Kallmes	Interventional neurology	10.1159/000446503		No detailed information on cranial nerve palsies
45	2017	Miyachi	Neurointervention	10.5469/neuroint.2017.12.2.83	Yes	
46	2017	Bhogal	Frontiers in neurology	10.3389/fneur.2017.00381	No	No detailed information on cranial nerve palsies
47	2017	Griessenauer	Neurosurgery	10.1093/neuros/nyw110		At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
48	2017	Briganti	Journal of neurointerventional surgery	10.1136/neurintsurg-2016-012502		Less than 10 patients with cranial nerve palsies treated by flow diversion
49	2017	Peschillo	Operative Neurosurgery	10.1093/ons/opx032	No	No detailed information on cranial nerve palsies
50	2017	Miyachi	Journal of Stroke and Cerebrovascular Diseases	10.1016/j.jstrokecerebrovasdis.2016.12.023	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
51	2017	Becske	Neurosurgery	10.1093/neuros/nyw014	No	No detailed information on cranial nerve palsies
52	2018	Silva	Journal of neurosurgery	10.3171/2018.1.JNS171774	Yes	
53	2018	ReXiaTi	Bio-medical materials and engineering	10.3233/BME-171718	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
54	2018	Killer-Oberpfalzer	American Journal of Neuroradiology	10.3174/ajnr.A5592	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
55	2018	Byvaltsev	Vestnik Rossiiskoi Akademii Meditsinskikh Nauk	10.15690/vramn918	No	Russian language
56	2018	Oishi	Neurologia Medico-Chirurgica	10.2176/nmc.oa.2018-0148	Yes	
57	2018	Pierot	Journal of neurointerventional surgery	10.1136/neurintsurg-2017-013559	No	No detailed information on cranial nerve palsies
58	2019	Sweid	World neurosurgery	10.1016/j.wneu.2019.07.115	No	No detailed information on cranial nerve palsies
59	2019	Yan	World neurosurgery	10.1016/j.wneu.2019.01.082	Yes	
60	2019	Pierot	Journal of neurointerventional surgery	10.1136/neurintsurg-2018-014261	No	No detailed information on cranial nerve palsies
61	2019	Kühn	Interventional neuroradiology	10.1177/1591019918792536	No	No detailed information on cranial nerve palsies
62	2019	Wang	Frontiers in Neurology	10.3389/fneur.2019.01191	Yes	
63	2019	Griessenauer	Neurosurgery	10.1093/neuros/nyy572	No	No detailed information on cranial nerve palsies
64	2019	Oğuz	Turkish Journal of Medical Sciences	10.3906/sag-1906-116	No	No detailed information on cranial nerve palsies
65	2019	Meyers	Stroke	10.1161/STROKEAHA.118.024135	No	No detailed information on cranial nerve palsies
66	2020	Nurminen	Clinical neurology and neurosurgery	10.1016/j.clineuro.2020.105782	No	Mixed patients with new (n=1) and existing (n=12) symptoms, not possible to differentiate
67	2020	Binh	Heliyon	10.1016/j.heliyon.2020.e03356	No	No detailed information on cranial nerve palsies
68	2020	Lv	The neuroradiology journal	10.1177/1971400919898109	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
69	2020	Foreman	World neurosurgery	10.1016/j.wneu.2019.11.084	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
70	2020	Daglioglu	Turkish neurosurgery	10.5137/1019-5149.JTN.25776-19.2	No	No detailed information on cranial nerve palsies
71	2020	Piano	Journal of Neurosurgery	10.3171/2019.1.JNS183005	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
72	2021	Catapano	Journal of neurosurgery	10.3171/2021.5.JNS211149	No	No detailed information on cranial nerve palsies
73	2021	Lee	The neuroradiology journal	10.1177/19714009211013487	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
74	2021	Kunert	Scientific reports	10.1038/s41598-021-87498-z		Less than 10 patients with cranial nerve palsies treated by flow diversion
75	2021	Link	Journal of clinical neuroscience : official journal of the	10.1016/j.jocn.2021.01.016	No	No detailed information on cranial nerve palsies
76	2021	Boulouis	Journal of neurointerventional surgery	10.1136/neurintsurg-2021-018188	Yes	
77	2022	Fehrenbach	Brain Sciences	10.3390/brainsci12030330	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
78	2022	Fujii	Neurologia Medico-Chirurgica	10.2176/nmc.oa.2021-0203	Yes	
		2nd search on 22nd May:				
79	2022	Xu	Acta Neurochirurgica	10.1007/s00701-022-05239-1	Yes	
80	2022	Lee	AJNR. American journal of neuroradiology	10.3174/ajnr.A7498	Yes	

Supplemental Table 2: Patient demographics and aneurysm characteristics

Study	Patients with NOS[$] (%)	Visual symptoms only	Oculomotor symptoms only	Combined symptoms	Female (%)	Age (mean +/- SD)	Intradural aneurysms (%)	Extradural aneurysms (%)	Aneurysm size (mean +/- SD)
Yu et al[22]	14	0 (0%)	14 (100%)	0 (0%)	NR[#]	NR	NR	NR	<10 mm: 6; 10-25 mm: 4; >25 mm: 3
Szikora et al[28]	16	6 ((37.5%)	10 (62.5%)	0 (0%)	NR	NR	NR	NR	NR
O'Kelly et al[26]	36	12 (33.3%)	24 (66.7%)	0 (0%)	NR	NR	NR	NR	NR
Moon et al[35]	19	2 (10.5%)	17 (84.2%)	1 (5.3%)	14	65.8 +/- 14.5 years	5 (26.3%)	14 (73.7%)	17.7 +/- 7.8 mm
Tanweer et al[37]	19*	NR	NR	NR	NR	NR	0 (0%)	19 (100%)	NR
Zanaty et al[34]	51	0 (0%)	51 (100%)	0 (0%)	NR	NR	0 (0%)	51 (100%)	NR
Zhou et al[38]	11	4 (36.4%)	7 (63.6%)	0 (0%)	NR	NR	NR	NR	NR
Puffer et al[31]	24	1 (4.2%)	23 (85.8%)	0 (0%)	22 (91.7%)	73 +/- 10.1 years	0 (0%)	24 (100%)	22 +/- 4.6 mm
Sahlein et al[46]	39	13 (33.3%)	18 (46.2%)	8 (20.5%)	22 (56.4%)	58 +/- 10.8 years	14 (35.9%)[§]	24 (61.5%)[§]	22 +/- 5.9 mm
Zanaty et al[45]	12	12 (100%)	0 (0%)	0 (0%)	NR	NR	12 (100%)	0 (0%)	NR
Breu et al[49]	10	1 (10%)	5 (50%)	4 (40%)	10 (100%)	62.5 +/- 9.3 years	NR	NR	15.7 +/- 3.9 mm
Kim et al[53]	18	NR	NR	NR	NR	NR	NR	NR	NR
Brown et al[54]	45	10 (22.2%)	33 (73.3%)	2 (4.4%)	42 (93.3%)	64.7 years	19	26	18.6 mm
Miyachi et al[64]	18	0 (0%)	17 (94.4%)	1 (5.6%)	17 (94.4%)	70.8 +/- 11.8 years	0 (0%)	18 (100%)	21.7 +/- 7.1 mm
Silva et al[71]	15	15 (100%)	0 (0%)	0 (0%)	NR	NR	NR	NR	NR
Oishi et al[73]	38	10 (26.3%)	28 (73.7%)	0 (0%)	NR	NR	NR	NR	NR
Yan et al[79]	50	NR	NR	NR	NR	NR	NR	NR	NR
Wang et al[76]	22	15 (68.2%)	3 (13.6%)	4 (18.2%)	17 (77.3%)	53.5 +/- 11.4 years	NR	NR	10-25 mm: 11; >25 mm: 11
Boulouis et al[7]	54	15 (27.8%)	21 (38.9%)	18 (33.3%)	48 (88.9%)	59.2 +/- 15.9 years	33 (61.1%)	21 (38.9%)	16.2 +/- 7.6 mm
Fujii et al[93]	29	7 (24.1%)	22 (75.9%)	0 (0%)	NR	NR	NR	NR	NR
Xu et al[95]	26	26 (100%)	0 (0%)	0 (0%)	NR	NR	26 (100%)	0 (0%)	NR
Lee et al[94]	28	NR	NR	NR	NR	NR	NR	NR	NR

[$]NOS = neuro-ophthalmological symptoms induced by ICA aneurysm, treated with flow diversion

*Only data on cavernous aneurysms reported

'F/U = Follow-up

[#]Not reported

[§]Discrepancy in the manuscript

Supplemental Table 3: Neuro-ophthalmological outcomes in relation to time from symptom onset to treatment

	Within first month		Beyond first month	
Study	**Complete recovery**	**Improvement***	**Complete recovery**	**Improvement**
Brown et al[54]	NR[#]	11/11 (100%)	NR	12/27 (44.4%)
Wang et al[76]	NR	8/11 (72.7%)	NR	4/11 (36.4%)
Boulouis et al[7]	11/22 (50%)	19/22 (86.4%)	8/28 (28.6%)	18/28 (64.3%)

*Improvement = Complete & partial recovery
[#]Not reported

Supplemental Table 4: Visual and oculomotor outcomes

Study	Patients with NOS[$]	Visual			Oculomotor		
		Visual symptoms only with F/U'	Complete recovery	Improvement	Oculomotor symptoms only with F/U'	Complete recovery	Improvement
Yu et al[22]	14	0	-	-	13	10	13
Szikora et al[28]	16	6	3	5	10	7	10
O'Kelly et al[26]	36	9	1	5	18	11	13
Moon et al[35]	19	2	1	1	17	3	13
Tanweer et al[37]	19*	NR[#]	-	-	NR	-	-
Zanaty et al[34]	51	0	-	-	51	36	47
Zhou et al[38]	11	4	1	1	7	4	7
Puffer et al[31]	24	1	1	1	19	17	17
Sahlein et al[46]	39	13	0	7	22	1	14
Zanaty et al[45]	12	12	9	12	0	-	-
Breu et al[49]	10	1	0	0	5	0	5
Kim et al[53]	18	NR	-	-	NR	-	-
Brown et al[54]	45	10	NR	NR	33	NR	NR
Miyachi et al[64]	18	0	-	-	17	6	15
Silva et al[71]	15	15	NR	15	0	-	-
Oishi et al[73]	38	10	NR	3	28	NR	15
Yan et al[79]	50	NR	-	-	NR	-	-
Wang et al[76]	22	15	NR	7	3	NR	3
Boulouis et al[7]	54	14	0	5	20	5	13
Fujii et al[93]	29	7	NR	3	22	NR	17
Xu et al[95]	26	26	NR	20	0	-	-
Lee et al[94]	28	NR	-	-	NR	-	-

[$]NOS = neuro-ophthalmological symptoms induced by ICA aneurysm, treated with flow diversion

*Only data on cavernous aneurysms reported

'F/U = Follow-up

[#]Not reported

Supplemental Table 5: Complications and anatomical results

Study	Patients	Treatment-related complications		Anatomical result			
		Morbidity	Mortality	Patient with anatomical F/U`	F/U' (mean +/- SD)	Complete occlusion	Incomplete occlusion
Yu et al[22]	14	0	1	13	3.5 months (median)	7	6
Szikora et al[28]	16	NR	NR	NR	NR	NR	NR
O'Kelly et al[26]	36	NR	NR	NR	NR	NR	NR
Moon et al[35]	19	0	0	17	9.7 +/- 6.3 months	9	8
Tanweer et al[37]	19*	NR	NR	NR	NR	NR	NR
Zanaty et al[34]	51	NR	NR	NR	NR	NR	NR
Zhou et al[38]	11	0	0	NR	NR	NR	NR
Puffer et al[31]	24	0	0	20	10.3 +/- 7.6 months	14	6
Sahlein et al[46]	39	NR	NR	NR	NR	NR	NR
Zanaty et al[45]	12	0	0	NR	NR	NR	NR
Breu et al[49]	10	NR	1	8	NR	5	3
Kim et al[53]	18	NR	NR	NR	NR	NR	NR
Brown et al[54]	45	1	0	40	8.4 months (mean)	26	14
Miyachi et al[64]	18	0	0	18	6 months	11	7
Silva et al[71]	15	0	0	NR	NR	NR	NR
Oishi et al[73]	38	NR	NR	NR	NR	NR	NR
Yan et al[79]	50	NR	NR	NR	NR	NR	NR
Wang et al[76]	22	2	1	21	12.2 +/- 1.7 months	21	0
Boulouis et al[7]	54	4	2	50	13.3 +/. 10.5 months	37	13
Fujii et al[93]	29	NR	NR	NR	NR	NR	NR
Xu et al[95]	26	NR	NR	26	NR	23	3
Lee et al[94]	28	NR	NR	NR	NR	NR	NR

[$]NOS = neuro-ophthalmological symptoms induced by ICA aneurysm, treated with flow diversion

*PM = Prospective multi-center; PS = Prospective single-center; RS = Retrospective single-center; RM = Retrospective multi-center

'F/U = Follow-up

[#]Not reported

SUPPLEMENTAL FIGURES



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

Supplemental Fig. 1: Prisma flow diagram



Supplemental Fig. 2: Funnel plots for complete recovery (A), improvement (B), transient (C) and permanent worsening (D).



Supplemental Fig. 3: Funnels plots for complete visual recovery (A) and improvement (B) and on complete oculomotor recovery (C) and improvement (D).



Supplemental Fig. 4: Forest plot (A) and corresponding funnel plot (B) for complete aneurysm occlusion.



Supplemental Fig. 5: Funnel plots for morbidity (A) and mortality (B).



Supplemental Fig. 6: Bubble plots depicting the effect size (i.e. complete NOS recovery or improvement) in association with patient age (A, B), follow-up (C, D) and study size (E, F).

ICMJE DISCLOSURE FORM

Date: 7/13/2022

Your Name: Ani Cuberi

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/14/2021

Your Name: Daniel P. O. Kaiser

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Joachim Herz Stiftung	Research grant
		Else Kröner Fresenius Center for Digital Health	Research grant
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
		Deutsche Gesellschaft für Neuroradiologie	Board member

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☐ **None**	
		Phenox Inc.	Stents for research purpose
13	Other financial or non-financial interests	☒ **None**	
		Brainomix	Research agreement without payments.

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/15/2022

Your Name: Jennifer Linn

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/14/2022

Your Name: Matthias GAWLITZA

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Else Kröner Fresenius Center for Digital Health	Research grant
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
		Phenox	
		Microvention	Proctoring
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
		Phenox	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
		Microvention	Study on the FRED flow diverter, member of the CEC
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
		Phenox	Received stents for research purposes
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

SUPPLEMENTAL MATERIAL

Search algorithm

("Aneurysm"[MeSH] OR "aneurysm"[tiab]) AND ("Carotid Artery, Internal"[MeSH] OR "Ophthalmic Artery"[MeSH] OR "ophthalmic"[tiab] OR "paraclinoid"[tiab] OR "clinoidal"[tiab] OR "superior hypophyseal"[tiab] OR "cavernous"[tiab] OR "petrous"[tiab] OR "visual"[tiab] OR "compressive"[tiab] OR "compression"[tiab] OR "cranial nerve"[tiab]) AND ("flow diversion"[tiab] OR "flow diverter"[tiab] OR "flow diverter"[tiab] OR "flow diverting" OR "Pipeline embolization device" OR Silk OR Fred OR P64 OR Surpass OR "Pipeline flex" OR Tubridge). [tiab] and [MeSH] arguments were removed for literature search on Scopus and Web of Science.

Supplemental Table 1: Study selection

No.	Year	First Author	Journal	DOI	Inclusion	Reason for exclusion
1	2010	Lubicz	Stroke	10.1161/STROKEAHA.110.589911	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
2	2010	Szikora	AJNR. American journal of neuroradiology	10.3174/ajnr.A2023	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
3	2011	Leonardi	Interventional neuroradiology	10.1177/159101991101700305	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
4	2011	Nelson	AJNR. American journal of neuroradiology	10.3174/ajnr.A2421	No	No detailed information on cranial nerve palsies
5	2012	Lanzino	AJNR. American journal of neuroradiology	10.3174/ajnr.A3207	No	No detailed information on cranial nerve palsies
6	2012	Puffer	Journal of neurosurgery	10.3171/2011.11.JNS111612	No	No detailed information on cranial nerve palsies
7	2012	Briganti	Neuroradiology	10.1007/s00234-012-1047-3	No	No detailed information on cranial nerve palsies
8	2012	Berge	American Journal of Neuroradiology	10.3174/ajnr.A2907	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
9	2012	Kan	Neurosurgery	10.1227/NEU.0b013e31827060d9	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
10	2012	Yu	Radiology	10.1148/radiol.12120422	Yes	
11	2013	Malatesta	La Radiologia medica	10.1007/s11547-013-0944-9	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
12	2013	Szikora	AJNR. American journal of neuroradiology	10.3174/ajnr.A3547	Yes	
13	2013	O'Kelly	AJNR. American journal of neuroradiology	10.3174/ajnr.A3224	Yes	
14	2013	Colby	Journal of neurointerventional surgery	10.1136/neurintsurg-2012-010299	No	No detailed information on cranial nerve palsies
15	2013	Toma	British Journal of Neurosurgery	10.3109/02688697.2013.793292	No	No detailed information on cranial nerve palsies
16	2013	Chalouhi	Stroke	10.1161/STROKEAHA.113.001785	No	No detailed information on cranial nerve palsies
17	2013	De Vries	Stroke	10.1161/STROKEAHA.111.000434	No	No detailed information on cranial nerve palsies
18	2014	Buyukkaya	Interventional neuroradiology	10.15274/INR-2014-10070	No	No detailed information on cranial nerve palsies
19	2014	Moon	Journal of neurosurgery	10.3171/2014.7.JNS132677	Yes	
20	2014	Tanweer	AJNR. American journal of neuroradiology	10.3174/ajnr.A4081	Yes	
21	2014	Zanaty	Stroke	10.1161/STROKEAHA.114.006247	Yes	
22	2014	Heller	Journal of neurosurgery	10.3171/2014.3.JNS131493	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
23	2014	Zhou	AJNR. American journal of neuroradiology	10.3174/ajnr.A3925	Yes	
24	2014	Moon	Neurological research	10.1179/1743132814Y.0000000322	No	No detailed information on cranial nerve palsies
25	2014	Puffer	AJNR. American journal of neuroradiology	10.3174/ajnr.A3826	Yes	
26	2014	Chalouhi	AJNR. American journal of neuroradiology	10.3174/ajnr.A3957	No	No detailed information on cranial nerve palsies
27	2015	Di Maria	AJNR. American journal of neuroradiology	10.3174/ajnr.A4437	No	No detailed information on cranial nerve palsies
28	2015	Sahlein	Journal of neurosurgery	10.3171/2014.12.JNS141777	Yes	
29	2015	Zanaty	Neurosurgery	10.1227/NEU.0000000000000607	Yes	
30	2015	Rouchaud	AJNR. American journal of neuroradiology	10.3174/ajnr.A4129	No	Less than 10 patients with cranial nerve palsies
31	2015	Wakhloo	AJNR. American journal of neuroradiology	10.3174/ajnr.A4078		At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
32	2015	Alghamdi	Expert Review of Medical Devices	10.1586/17434440.2015.1093413	No	Review article
33	2015	Fischer	AJNR. American journal of neuroradiology	10.3174/ajnr.A4420	No	No detailed information on cranial nerve palsies
34	2015	Shimizu	Acta neurochirurgica	10.1007/s00701-014-2251-1	No	No flow diverter devices applied
35	2015	Oh	Clinical neurology and neurosurgery	10.1016/j.clineuro.2014.11.008	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
36	2015	Zhu	World neurosurgery	10.1016/j.wneu.2015.07.036	No	Review article
37	2016	Jevsek	Radiology and oncology	10.1515/raon-2016-0049		Less than 10 patients with cranial nerve palsies treated by flow diversion
38	2016	Kaya	Turkish neurosurgery	10.5137/1019-5149.JTN.14760-15.0	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
39	2016	Breu	Radiology research and practice	10.1155/2016/2187275	Yes	
40	2016	Kim	Neurointervention	10.5469/neuroint.2016.11.1.10	Yes	
41	2016	Brown	Journal of neurosurgery	10.3171/2015.4.JNS142790	Yes	
42	2016	Durst	Journal of neurointerventional surgery	10.1136/neurintsurg-2015-011887	No	No detailed information on cranial nerve palsies
43	2016	Burrows	AJNR. American journal of neuroradiology	10.3174/ajnr.A4835	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
44	2016	Kallmes	Interventional neurology	10.1159/000446503		No detailed information on cranial nerve palsies
45	2017	Miyachi	Neurointervention	10.5469/neuroint.2017.12.2.83	Yes	
46	2017	Bhogal	Frontiers in neurology	10.3389/fneur.2017.00381	No	No detailed information on cranial nerve palsies
47	2017	Griessenauer	Neurosurgery	10.1093/neuros/nyw110		At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
48	2017	Briganti	Journal of neurointerventional surgery	10.1136/neurintsurg-2016-012502		Less than 10 patients with cranial nerve palsies treated by flow diversion
49	2017	Peschillo	Operative Neurosurgery	10.1093/ons/opx032	No	No detailed information on cranial nerve palsies
50	2017	Miyachi	Journal of Stroke and Cerebrovascular Diseases	10.1016/j.jstrokecerebrovasdis.2016.12.023	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
51	2017	Becske	Neurosurgery	10.1093/neuros/nyw014	No	No detailed information on cranial nerve palsies
52	2018	Silva	Journal of neurosurgery	10.3171/2018.1.JNS171774	Yes	
53	2018	ReXiaTi	Bio-medical materials and engineering	10.3233/BME-171718	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
54	2018	Killer-Oberpfalzer	American Journal of Neuroradiology	10.3174/ajnr.A5592	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
55	2018	Byvaltsev	Vestnik Rossiiskoi Akademii Meditsinskikh Nauk	10.15690/vramn918	No	Russian language
56	2018	Oishi	Neurologia Medico-Chirurgica	10.2176/nmc.oa.2018-0148	Yes	
57	2018	Pierot	Journal of neurointerventional surgery	10.1136/neurintsurg-2017-013559	No	No detailed information on cranial nerve palsies
58	2019	Sweid	World neurosurgery	10.1016/j.wneu.2019.07.115	No	No detailed information on cranial nerve palsies
59	2019	Yan	World neurosurgery	10.1016/j.wneu.2019.01.082	Yes	
60	2019	Pierot	Journal of neurointerventional surgery	10.1136/neurintsurg-2018-014261	No	No detailed information on cranial nerve palsies
61	2019	Kühn	Interventional neuroradiology	10.1177/1591019918792536	No	No detailed information on cranial nerve palsies
62	2019	Wang	Frontiers in Neurology	10.3389/fneur.2019.01191	Yes	
63	2019	Griessenauer	Neurosurgery	10.1093/neuros/nyy572	No	No detailed information on cranial nerve palsies
64	2019	Oğuz	Turkish Journal of Medical Sciences	10.3906/sag-1906-116	No	No detailed information on cranial nerve palsies
65	2019	Meyers	Stroke	10.1161/STROKEAHA.118.024135	No	No detailed information on cranial nerve palsies
66	2020	Nurminen	Clinical neurology and neurosurgery	10.1016/j.clineuro.2020.105782	No	Mixed patients with new (n=1) and existing (n=12) symptoms, not possible to differentiate
67	2020	Binh	Heliyon	10.1016/j.heliyon.2020.e03356	No	No detailed information on cranial nerve palsies
68	2020	Lv	The neuroradiology journal	10.1177/1971400919898109	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
69	2020	Foreman	World neurosurgery	10.1016/j.wneu.2019.11.084	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
70	2020	Daglioglu	Turkish neurosurgery	10.5137/1019-5149.JTN.25776-19.2	No	No detailed information on cranial nerve palsies
71	2020	Piano	Journal of Neurosurgery	10.3171/2019.1.JNS183005	No	At least 10 eligible patients, but insufficient information on clinical symptoms and follow-up
72	2021	Catapano	Journal of neurosurgery	10.3171/2021.5.JNS211149	No	No detailed information on cranial nerve palsies
73	2021	Lee	The neuroradiology journal	10.1177/19714009211013487	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
74	2021	Kunert	Scientific reports	10.1038/s41598-021-87498-z		Less than 10 patients with cranial nerve palsies treated by flow diversion
75	2021	Link	Journal of clinical neuroscience : official journal of the	10.1016/j.jocn.2021.01.016	No	No detailed information on cranial nerve palsies
76	2021	Boulouis	Journal of neurointerventional surgery	10.1136/neurintsurg-2021-018188	Yes	
77	2022	Fehrenbach	Brain Sciences	10.3390/brainsci12030330	No	Less than 10 patients with cranial nerve palsies treated by flow diversion
78	2022	Fujii	Neurologia Medico-Chirurgica	10.2176/nmc.oa.2021-0203	Yes	
		2nd search on 22nd May:				
79	2022	Xu	Acta Neurochirurgica	10.1007/s00701-022-05239-1	Yes	
80	2022	Lee	AJNR. American journal of neuroradiology	10.3174/ajnr.A7498	Yes	

Supplemental Table 2: Patient demographics and aneurysm characteristics

Study	Patients with NOS[$] (%)	Visual symptoms only	Oculomotor symptoms only	Combined symptoms	Female (%)	Age (mean +/- SD)	Intradural aneurysms (%)	Extradural aneurysms (%)	Aneurysm size (mean +/- SD)
Yu et al[22]	14	0 (0%)	14 (100%)	0 (0%)	NR[#]	NR	NR	NR	<10 mm: 6; 10-25 mm: 4; >25 mm: 3
Szikora et al[28]	16	6 ((37.5%)	10 (62.5%)	0 (0%)	NR	NR	NR	NR	NR
O'Kelly et al[26]	36	12 (33.3%)	24 (66.7%)	0 (0%)	NR	NR	NR	NR	NR
Moon et al[35]	19	2 (10.5%)	17 (84.2%)	1 (5.3%)	14	65.8 +/- 14.5 years	5 (26.3%)	14 (73.7%)	17.7 +/- 7.8 mm
Tanweer et al[37]	19*	NR	NR	NR	NR	NR	0 (0%)	19 (100%)	NR
Zanaty et al[34]	51	0 (0%)	51 (100%)	0 (0%)	NR	NR	0 (0%)	51 (100%)	NR
Zhou et al[38]	11	4 (36.4%)	7 (63.6%)	0 (0%)	NR	NR	NR	NR	NR
Puffer et al[31]	24	1 (4.2%)	23 (85.8%)	0 (0%)	22 (91.7%)	73 +/- 10.1 years	0 (0%)	24 (100%)	22 +/- 4.6 mm
Sahlein et al[46]	39	13 (33.3%)	18 (46.2%)	8 (20.5%)	22 (56.4%)	58 +/- 10.8 years	14 (35.9%)[§]	24 (61.5%)[§]	22 +/- 5.9 mm
Zanaty et al[45]	12	12 (100%)	0 (0%)	0 (0%)	NR	NR	12 (100%)	0 (0%)	NR
Breu et al[49]	10	1 (10%)	5 (50%)	4 (40%)	10 (100%)	62.5 +/- 9.3 years	NR	NR	15.7 +/- 3.9 mm
Kim et al[53]	18	NR	NR	NR	NR	NR	NR	NR	NR
Brown et al[54]	45	10 (22.2%)	33 (73.3%)	2 (4.4%)	42 (93.3%)	64.7 years	19	26	18.6 mm
Miyachi et al[64]	18	0 (0%)	17 (94.4%)	1 (5.6%)	17 (94.4%)	70.8 +/- 11.8 years	0 (0%)	18 (100%)	21.7 +/- 7.1 mm
Silva et al[71]	15	15 (100%)	0 (0%)	0 (0%)	NR	NR	NR	NR	NR
Oishi et al[73]	38	10 (26.3%)	28 (73.7%)	0 (0%)	NR	NR	NR	NR	NR
Yan et al[79]	50	NR	NR	NR	NR	NR	NR	NR	NR
Wang et al[76]	22	15 (68.2%)	3 (13.6%)	4 (18.2%)	17 (77.3%)	53.5 +/- 11.4 years	NR	NR	10-25 mm: 11; >25 mm: 11
Boulouis et al[7]	54	15 (27.8%)	21 (38.9%)	18 (33.3%)	48 (88.9%)	59.2 +/- 15.9 years	33 (61.1%)	21 (38.9%)	16.2 +/- 7.6 mm
Fujii et al[93]	29	7 (24.1%)	22 (75.9%)	0 (0%)	NR	NR	NR	NR	NR
Xu et al[95]	26	26 (100%)	0 (0%)	0 (0%)	NR	NR	26 (100%)	0 (0%)	NR
Lee et al[94]	28	NR	NR	NR	NR	NR	NR	NR	NR

[$]NOS = neuro-ophthalmological symptoms induced by ICA aneurysm, treated with flow diversion

*Only data on cavernous aneurysms reported

'F/U = Follow-up

[#]Not reported

[§]Discrepancy in the manuscript

Supplemental Table 3: Neuro-ophthalmological outcomes in relation to time from symptom onset to treatment

	Within first month		Beyond first month	
Study	**Complete recovery**	**Improvement***	**Complete recovery**	**Improvement**
Brown et al[54]	NR[#]	11/11 (100%)	NR	12/27 (44.4%)
Wang et al[76]	NR	8/11 (72.7%)	NR	4/11 (36.4%)
Boulouis et al[7]	11/22 (50%)	19/22 (86.4%)	8/28 (28.6%)	18/28 (64.3%)

*Improvement = Complete & partial recovery
[#]Not reported

Supplemental Table 4: Visual and oculomotor outcomes

Study	Patients with NOS[$]	Visual			Oculomotor		
		Visual symptoms only with F/U'	Complete recovery	Improvement	Oculomotor symptoms only with F/U'	Complete recovery	Improvement
Yu et al[22]	14	0	-	-	13	10	13
Szikora et al[28]	16	6	3	5	10	7	10
O'Kelly et al[26]	36	9	1	5	18	11	13
Moon et al[35]	19	2	1	1	17	3	13
Tanweer et al[37]	19*	NR[#]	-	-	NR	-	-
Zanaty et al[34]	51	0	-	-	51	36	47
Zhou et al[38]	11	4	1	1	7	4	7
Puffer et al[31]	24	1	1	1	19	17	17
Sahlein et al[46]	39	13	0	7	22	1	14
Zanaty et al[45]	12	12	9	12	0	-	-
Breu et al[49]	10	1	0	0	5	0	5
Kim et al[53]	18	NR	-	-	NR	-	-
Brown et al[54]	45	10	NR	NR	33	NR	NR
Miyachi et al[64]	18	0	-	-	17	6	15
Silva et al[71]	15	15	NR	15	0	-	-
Oishi et al[73]	38	10	NR	3	28	NR	15
Yan et al[79]	50	NR	-	-	NR	-	-
Wang et al[76]	22	15	NR	7	3	NR	3
Boulouis et al[7]	54	14	0	5	20	5	13
Fujii et al[93]	29	7	NR	3	22	NR	17
Xu et al[95]	26	26	NR	20	0	-	-
Lee et al[94]	28	NR	-	-	NR	-	-

[$]NOS = neuro-ophthalmological symptoms induced by ICA aneurysm, treated with flow diversion

*Only data on cavernous aneurysms reported

'F/U = Follow-up

[#]Not reported

Supplemental Table 5: Complications and anatomical results

Study	Patients	Treatment-related complications		Anatomical result			
		Morbidity	Mortality	Patient with anatomical F/U`	F/U' (mean +/- SD)	Complete occlusion	Incomplete occlusion
Yu et al[22]	14	0	1	13	3.5 months (median)	7	6
Szikora et al[28]	16	NR	NR	NR	NR	NR	NR
O'Kelly et al[26]	36	NR	NR	NR	NR	NR	NR
Moon et al[35]	19	0	0	17	9.7 +/- 6.3 months	9	8
Tanweer et al[37]	19*	NR	NR	NR	NR	NR	NR
Zanaty et al[34]	51	NR	NR	NR	NR	NR	NR
Zhou et al[38]	11	0	0	NR	NR	NR	NR
Puffer et al[31]	24	0	0	20	10.3 +/- 7.6 months	14	6
Sahlein et al[46]	39	NR	NR	NR	NR	NR	NR
Zanaty et al[45]	12	0	0	NR	NR	NR	NR
Breu et al[49]	10	NR	1	8	NR	5	3
Kim et al[53]	18	NR	NR	NR	NR	NR	NR
Brown et al[54]	45	1	0	40	8.4 months (mean)	26	14
Miyachi et al[64]	18	0	0	18	6 months	11	7
Silva et al[71]	15	0	0	NR	NR	NR	NR
Oishi et al[73]	38	NR	NR	NR	NR	NR	NR
Yan et al[79]	50	NR	NR	NR	NR	NR	NR
Wang et al[76]	22	2	1	21	12.2 +/- 1.7 months	21	0
Boulouis et al[7]	54	4	2	50	13.3 +/. 10.5 months	37	13
Fujii et al[93]	29	NR	NR	NR	NR	NR	NR
Xu et al[95]	26	NR	NR	26	NR	23	3
Lee et al[94]	28	NR	NR	NR	NR	NR	NR

[$]NOS = neuro-ophthalmological symptoms induced by ICA aneurysm, treated with flow diversion

*PM = Prospective multi-center; PS = Prospective single-center; RS = Retrospective single-center; RM = Retrospective multi-center

'F/U = Follow-up

[#]Not reported

SUPPLEMENTAL FIGURES



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

Supplemental Fig. 1: Prisma flow diagram



Supplemental Fig. 2: Funnel plots for complete recovery (A), improvement (B), transient (C) and permanent worsening (D).



Supplemental Fig. 3: Funnels plots for complete visual recovery (A) and improvement (B) and on complete oculomotor recovery (C) and improvement (D).



Supplemental Fig. 4: Forest plot (A) and corresponding funnel plot (B) for complete aneurysm occlusion.



Supplemental Fig. 5: Funnel plots for morbidity (A) and mortality (B).



Supplemental Fig. 6: Bubble plots depicting the effect size (i.e. complete NOS recovery or improvement) in association with patient age (A, B), follow-up (C, D) and study size (E, F).

ICMJE DISCLOSURE FORM

Date: 7/13/2022

Your Name: Ani Cuberi

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/14/2021

Your Name: Daniel P. O. Kaiser

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Joachim Herz Stiftung	Research grant
		Else Kröner Fresenius Center for Digital Health	Research grant
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
		Deutsche Gesellschaft für Neuroradiologie	Board member

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☐ **None**	
		Phenox Inc.	Stents for research purpose
13	Other financial or non-financial interests	☒ **None**	
		Brainomix	Research agreement without payments.

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/15/2022

Your Name: Jennifer Linn

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 7/14/2022

Your Name: Matthias GAWLITZA

Manuscript Title: Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis.

Manuscript Number (if known): neurintsurg-2022-019249.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Else Kröner Fresenius Center for Digital Health	Research grant
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
		Phenox	
		Microvention	Proctoring
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
		Phenox	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
		Microvention	Study on the FRED flow diverter, member of the CEC
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
		Phenox	Received stents for research purposes
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.